{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:19:12Z","timestamp":1794680352595,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It is estimated that over 111,000 people in the U.S. died from a drug overdose in the twelve-month period ending in July 2023. More than three-quarters of those deaths were attributed to opioids. Naloxone has long been available in healthcare facilities to reverse opioid overdose rapidly and safely but is not universally accessible for use in community settings where overdoses occur. We conducted a systematic literature review and meta-analysis to assess the effectiveness of overdose education and naloxone distribution (OEND) programs in three types of community settings to reduce overdose deaths among people who use opioids nonmedically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched electronic databases, including Medline (OVID), Embase (OVID), Psycinfo (OVID), and Global Health (OVID), for peer-reviewed studies of OEND programs published during 2003\u20132018 (Group 1) that reported overdose outcomes individual level survivals or deaths immediately following naloxone administration. The PRISMA checklist guided screening, quality assessment, and data abstraction. We later identified studies published during 2018\u20132022 (Group 2), when drug usage and fentanyl-related overdose deaths notably increased, differed from earlier ones. We conducted meta-analyses on both Groups using random effects models to estimate summary survival proportions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 44 Group 1 studies published during 2003\u20132018, survival did not differ by time (year), location, naloxone dose, or route of administration, but studies of OEND programs serving people who use drugs reported 98.3% (95% CI: 97.5\u201398.8) survival; those serving family of people who use drugs or other community members reported 95.0% (95% CI: 91.4\u201397.1) survival; and those for police reported 92.4% (95% CI: 88.9\u201394.8) survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Five Group 2 studies (2018\u20132022) yielded similar results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Community-based naloxone distribution programs can be effective in preventing opioid overdose deaths. The paper demonstrates that in the face of increasing overdose deaths over time, survival after naloxone administration has been sustained. The very high survival rates provide clear evidence for public health to continue efforts to expand channels for naloxone distribution in community settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-025-22210-8","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T19:27:20Z","timestamp":1742930840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Leah S.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Becasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Doreson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin I.","family":"Meltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Edlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"22210_CR1","unstructured":"Centers for Disease Control and Prevention. Unintentional and undetermined poisoning deaths\u201411 states, 1990\u20132001. MMWR Morb Mortal Wkly Rep. 2004;53(11):233-8. PMID: 15041950."},{"key":"22210_CR2","first-page":"1","volume":"457","author":"MR Spencer","year":"2022","unstructured":"Spencer MR, Mini\u00f1o AM, Warner M. Drug overdose deaths in the united States, 2001\u20132021. NCHS Data Brief. 2022;457:1\u20138. PMID: 36598401.","journal-title":"NCHS Data Brief"},{"key":"22210_CR3","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.eclinm.2023.102079","volume":"61","author":"S Fujita-Imazu","year":"2023","unstructured":"Fujita-Imazu S, Xie J, Dhungel B, Wang X, Wang Y, Nguyen P, et al. Evolving trends in drug overdose mortality in the USA from 2000 to 2020: an age-period-cohort analysis. Lancet. 2023;61:102079. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102079. PMID: 37483548; PMCID: PMC10359729.","journal-title":"Lancet"},{"key":"22210_CR4","unstructured":"Carroll JJ, Green TC, Noonan RK. Evidence-based strategies for preventing opioid overdose: what\u2019s working in the United States. Atlanta, GA: Centers for Disease Control and Prevention, 2018. http:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2018-evidence-based-strategies.pdf"},{"key":"22210_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.10.013","volume":"157","author":"CS Davis","year":"2015","unstructured":"Davis CS, Carr D. Legal changes to increase access to Naloxone for opioid overdose reversal in the united States. Drug Alcohol Depend. 2015;157:112\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.10.013.","journal-title":"Drug Alcohol Depend"},{"key":"22210_CR6","doi-asserted-by":"crossref","unstructured":"Burris S, Norland J, Edlin B. Legal aspects of providing Naloxone to heroin users in the united States. Int J Drug Policy. 2001;12(3):237\u201348.","DOI":"10.1016\/S0955-3959(01)00080-9"},{"issue":"2","key":"22210_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/jurban\/jtg032","volume":"80","author":"KH Seal","year":"2003","unstructured":"Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J, Ciccarone D, Edlin BR. Attitudes about prescribing take-home Naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health. 2003;80(2):291\u2013301. https:\/\/doi.org\/10.1093\/jurban\/jtg032. PMID: 12791805; PMCID: PMC3456285.","journal-title":"J Urban Health"},{"key":"22210_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.trsl.2021.03.001","volume":"234","author":"AS Bennett","year":"2021","unstructured":"Bennett AS, Elliott L. Naloxone\u2019s role in the National opioid crisis-past struggles, current efforts, and future opportunities. Transl Res. 2021;234:43\u201357. https:\/\/doi.org\/10.1016\/j.trsl.2021.03.001. PMID: 33684591; PMCID: PMC8327685.","journal-title":"Transl Res"},{"key":"22210_CR9","first-page":"161","volume-title":"Undoing drugs: the untold story of harm reduction and the future of addiction","author":"M Szalavitz","year":"2021","unstructured":"Szalavitz M. Undoing overdose. Undoing drugs: the untold story of harm reduction and the future of addiction. New York, NY: Hachette Books. 2021;161\u201372."},{"issue":"1","key":"22210_CR10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1186\/s12889-022-13741-5","volume":"22","author":"AL Spector","year":"2022","unstructured":"Spector AL, Galletly CL, Christenson EA, Montaque HDG, Dickson-Gomez J. A qualitative examination of Naloxone access in three States: Connecticut, Kentucky, and Wisconsin. BMC Public Health. 2022;22(1):1387. https:\/\/doi.org\/10.1186\/s12889-022-13741-5. PMID: 35854278; PMCID: PMC9295344. https:\/\/pubmed.ncbi.nlm.nih.gov\/35854278\/.","journal-title":"BMC Public Health"},{"key":"22210_CR11","unstructured":"Centers for Disease Control and Prevention. Program and Operational Characteristics of Syringe Services Programs in the United States\u20142020 and 2021. National Syringes Services Programs Report 1. Published August 1, 2023."},{"key":"22210_CR12","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.15585\/mmwr.mm6933a2","volume":"69","author":"BH Lambdin","year":"2020","unstructured":"Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose education and Naloxone distribution within syringe service Programs \u2013 United States, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:1117\u201321.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"22210_CR13","first-page":"631","volume":"64","author":"E Wheeler","year":"2015","unstructured":"Wheeler E, Jones TS, Gilbert MK, Davidson PJ. Centers for disease C. Prevention. Opioid overdose prevention programs providing Naloxone to laypersons\u2014United States, 2014. Morb Mortal Wkly Rep. 2015;64(23):631\u20135.","journal-title":"Morb Mortal Wkly Rep"},{"key":"22210_CR14","volume-title":"Syringe services programs: A technical package of effective strategies and approaches for planning, design, and implementation","author":"Z Javed","year":"2020","unstructured":"Javed Z, Burk K, Facente S, Pegram L, Ali A, Asher A. Syringe services programs: A technical package of effective strategies and approaches for planning, design, and implementation. Atlanta, GA: US Department of Health and Human Services, National Center for HIV\/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease, Control and Prevention. 2020."},{"issue":"3","key":"22210_CR15","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/S2468-2667(21)00304-2","volume":"7","author":"MA Irvine","year":"2022","unstructured":"Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, et al. Estimating Naloxone need in the USA across Fentanyl, heroin, and prescription opioid epidemics: a modelling study. Lancet Public Health. 2022;7(3):e210\u20138. https:\/\/doi.org\/10.1016\/S2468-2667(21)00304-2.","journal-title":"Lancet Public Health"},{"key":"22210_CR16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0000000000000034","volume":"8","author":"AK Clark","year":"2014","unstructured":"Clark AK, Wilder CM, Winstanley EL. A systematic review of community opioid overdose prevention and Naloxone distribution programs. J Addict Med. 2014;8:153\u201363.","journal-title":"J Addict Med"},{"key":"22210_CR17","unstructured":"EMCDDA. Preventing Fatal Overdoses: A Systematic Review of the Effectiveness of Take-Home Naloxone. 2015. https:\/\/www.emcdda.europa.eu\/publications\/emcdda-papers\/naloxone-effectiveness_en"},{"issue":"2","key":"22210_CR18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1080\/08897077.2015.1010032","volume":"36","author":"SR Mueller","year":"2015","unstructured":"Mueller SR, Walley AJ, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and Naloxone prescribing: implications for translating community programming into clinical practice. Substance Abuse. 2015;36(2):240\u201353. https:\/\/doi.org\/10.1080\/08897077.2015.1010032.","journal-title":"Substance Abuse"},{"key":"22210_CR19","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take-home Naloxone programmes effective? Systematic review utilizing application of the Bradford hill criteria. Addiction. 2016;111:1177\u201387.","journal-title":"Addiction"},{"key":"22210_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40621-015-0041-8","volume":"2","author":"RE Giglio","year":"2015","unstructured":"Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander Naloxone administration and overdose education programs: a meta-analysis. Injury Epidemiol. 2015;2:10. https:\/\/doi.org\/10.1186\/s40621-015-0041-8.","journal-title":"Injury Epidemiol"},{"issue":"8","key":"22210_CR21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2021.306306","volume":"111","author":"A Razaghizad","year":"2021","unstructured":"Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, et al. The effect of overdose education and Naloxone distribution: an umbrella review of systematic reviews. AJPH. 2021;111(8):e1\u201312.","journal-title":"AJPH"},{"key":"22210_CR22","unstructured":"U.S. Overdose Deaths, by Select Drugs or Drug Categories, 1999\u20132022, https:\/\/nida.nih.gov\/sites\/default\/files\/images\/fig2-2024.jpg. In: NIDA. Drug Overdose Deaths: Facts and Figures. National Institute on Drug Abuse website. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates. August 21, 2024 Accessed November 6, 2024"},{"key":"22210_CR23","doi-asserted-by":"crossref","unstructured":"Zaza S, Wright-DeAg\u00fcero LK, Briss PA, et al. Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. American Journal of Preventive Medicine. 2000;18(1\u00a0S):44\u201374","DOI":"10.1016\/S0749-3797(99)00122-1"},{"key":"22210_CR24","doi-asserted-by":"crossref","unstructured":"Sanderson S, Tatt ID, Higgins PT. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotates bibliography. International Journal of Epidemiology. 2007;36:666\u2013676","DOI":"10.1093\/ije\/dym018"},{"key":"22210_CR25","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u2013341","DOI":"10.1016\/j.ijsu.2010.02.007"},{"key":"22210_CR26","doi-asserted-by":"publisher","unstructured":"Rando J, Broering D, Olson JE, Marco C, Evans SB. Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. American Journal of Emergency Medicine. 2015;33(9):1201\u20131204. https:\/\/doi.org\/10.1016\/j.ajem.2015.05.022","DOI":"10.1016\/j.ajem.2015.05.022"},{"key":"22210_CR27","doi-asserted-by":"publisher","unstructured":"Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, Rosenthal DM. Provision of naloxone to injection drug users as an overdose prevention strategy: Early evidence from a pilot study in New York City. Addictive Behaviors. 2006;31(5):907\u2013912. https:\/\/doi.org\/10.1016\/j.addbeh.2005.07.020","DOI":"10.1016\/j.addbeh.2005.07.020"},{"key":"22210_CR28","doi-asserted-by":"crossref","unstructured":"Strang J, Manning V, Mayet S, Best D, Titherington E, Santana L, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction. 2008;103(10):1648\u20131657","DOI":"10.1111\/j.1360-0443.2008.02314.x"},{"key":"22210_CR29","doi-asserted-by":"crossref","unstructured":"Wagner KD, Valente TW, Casanova M, Partovi SM, Mendenhall BM, Hundley JH, et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. International Journal of Drug Policy. 2010;21(3):186\u2013193","DOI":"10.1016\/j.drugpo.2009.01.003"},{"key":"22210_CR30","unstructured":"Yokell MA, Green TC, Bowman S, McKenzie M, Rich JD. Opioid overdose prevention and naloxone distribution in Rhode Island. Medicine and health, Rhode Island. 2011;94(8):240\u2013242"},{"key":"22210_CR31","doi-asserted-by":"publisher","unstructured":"Williams AV, Marsden J, Strang J. Training family members to manage heroin overdose and administer naloxone: Randomized trial of effects on knowledge and attitudes. Addiction. 2014;109(2):250\u2013259. https:\/\/doi.org\/10.1111\/add.12360","DOI":"10.1111\/add.12360"},{"key":"22210_CR32","doi-asserted-by":"publisher","unstructured":"Katzman JG, Takeda MY, Bhatt SR, Moya Balasch M, Greenberg N, Yonas H. An innovative model for naloxone use within an OTP Setting: A prospective cohort study. Journal of Addiction Medicine. 2018;12(2):113\u2013118. https:\/\/doi.org\/10.1097\/ADM.0000000000000374","DOI":"10.1097\/ADM.0000000000000374"},{"key":"22210_CR33","doi-asserted-by":"publisher","unstructured":"Thylstrup B, Hesse M, Jorgensen M, Thiesen H. One opioid user saving another: the first study of an opioid overdose-reversal and naloxone distribution program addressing hard-to-reach drug scenes in Denmark. Harm Reduct J. 2019;16(1):66. https:\/\/doi.org\/10.1186\/s12954-019-0328-0. PMID: 31,805,969. PMCID: PMC6896775. https:\/\/doi.org\/10.1186\/s12954-019-0328-0","DOI":"10.1186\/s12954-019-0328-0 10.1186\/s12954-019-0328-0"},{"key":"22210_CR34","doi-asserted-by":"publisher","unstructured":"Naumann RB, Durrance CP, Ranapurwala SI, Proescholdbell S, Childs R, Marshall SW, et al. Impact of a community-based naloxone distribution program on opioid overdose death rates. Drug Alcohol Depend. 2019;204:107536. https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.06.038. PMCID: PMC8107918. PMID: 31,494,440","DOI":"10.1016\/j.drugalcdep.2019.06.038"},{"key":"22210_CR35","doi-asserted-by":"publisher","unstructured":"Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. Medicine (Baltimore) 2019;98(23):e15987. https:\/\/doi.org\/10.1097\/MD.0000000000015987","DOI":"10.1097\/MD.0000000000015987"},{"key":"22210_CR36","doi-asserted-by":"crossref","unstructured":"Maxwell S; Bigg D; Stanczykiewicz K; Carlberg-Racich S. Prescribing Naloxone to Actively Injecting Heroin Users. Journal of Addictive Diseases, 2006;25:3,89\u201396","DOI":"10.1300\/J069v25n03_11"},{"key":"22210_CR37","doi-asserted-by":"crossref","unstructured":"Walley AY (2013), Xuan ZM, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad, A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in massachusetts: interrupted time series analysis. BMJ 2013;346(f174)","DOI":"10.1136\/bmj.f174"},{"key":"22210_CR38","doi-asserted-by":"crossref","unstructured":"Rowe C; Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin P. Neighborhood-level and spatial characteristics associated with lay naloxone reversal events and opioid overdose deaths. Journal of Urban Health. 2016;93(1):117\u2009\u2212\u200930","DOI":"10.1007\/s11524-015-0023-8"},{"key":"22210_CR39","doi-asserted-by":"publisher","unstructured":"Bird SM, McAuley A, Parry S, Hunter C. Effectiveness of Scotland\u2019s National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Addiction 2016;111(5):883\u2009\u2212\u200991. https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1111\/add.13265","DOI":"10.1111\/add.13265"},{"key":"22210_CR40","doi-asserted-by":"publisher","unstructured":"Bird SM, Strang J, Ashby D, Podmore J, Robertson JR, Welch S, Meade AM, Parmar M. External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial. Contemporary Clinical Trials Communications, 2017; Volume 5:100\u2013106. ISSN 2451\u20138654, https:\/\/doi.org\/10.1016\/j.conctc.2017.01.006","DOI":"10.1016\/j.conctc.2017.01.006"},{"key":"22210_CR41","doi-asserted-by":"publisher","unstructured":"Rowe C, Wheeler E, Stephen Jones T, Yeh C, Coffin PO. Community-Based Response to Fentanyl Overdose Outbreak, San Francisco, 2015. Journal of Urban Health 2019;96(1):6\u201311. https:\/\/doi.org\/10.1007\/s11524-018-0250-x. PMID: 29,725,887; PMCID: PMC6391290","DOI":"10.1007\/s11524-018-0250-x"},{"key":"22210_CR42","doi-asserted-by":"publisher","unstructured":"Koester S, Mueller SR, Raville L, Langegger S, Binswanger IA. Why are some people who have received overdose education and naloxone reticent to call Emergency Medical Services in the event of overdose? Int J Drug Policy 2017;48:115\u2013124. https:\/\/doi.org\/10.1016\/j.drugpo.2017.06.008","DOI":"10.1016\/j.drugpo.2017.06.008"},{"key":"22210_CR43","doi-asserted-by":"crossref","unstructured":"Latimore AD, Bergstein RS. \u201cCaught with a body\u201d yet protected by law? Calling 911 for opioid overdose in the context of the Good Samaritan Law. Int J Drug Policy 2017;50:82\u201389","DOI":"10.1016\/j.drugpo.2017.09.010"},{"key":"22210_CR44","doi-asserted-by":"publisher","unstructured":"van der Meulen E, Chu SKH, Butler-McPhee J. \u201cThat\u2019s why people don\u2019t call 911\u201d: Ending routine police attendance at drug overdoses. Int J Drug Policy 2021;88:103039. https:\/\/doi.org\/10.1016\/j.drugpo.2020.103039. PMID: 33,227,637","DOI":"10.1016\/j.drugpo.2020.103039"},{"key":"22210_CR45","doi-asserted-by":"publisher","unstructured":"Ashrafioun L, Gamble S, Herrmann M, Baciewicz G. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods. Subst Abus 2016;37(1):76\u201381. PMID: 26,514,071. https:\/\/doi.org\/10.1080\/08897077.2015.1110550","DOI":"10.1080\/08897077.2015.1110550"},{"key":"22210_CR46","doi-asserted-by":"crossref","unstructured":"Uyei J, Fiellin DA, Buchelli M, Rodriguez-Santana R, Braithwaite RS. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modeling study. Lancet Public Health. 2017;2:e133-40","DOI":"10.1016\/S2468-2667(17)30006-3"},{"key":"22210_CR47","doi-asserted-by":"publisher","unstructured":"H\u00e5kansson A, Alanko Blom\u00e9 M, Isendahl P, Landgren M, Malmqvist U, Troberg K. Distribution of intranasal naloxone to potential opioid overdose bystanders in Sweden: effects on overdose mortality in a full region-wide study. BMJ Open. 2024;14(1):e074152. https:\/\/doi.org\/10.1136\/bmjopen-2023-074152","DOI":"10.1136\/bmjopen-2023-074152"},{"key":"22210_CR48","doi-asserted-by":"publisher","unstructured":"Gooley B, Weston B, Colella MR, Farkas A. Outcomes of law enforcement officer administered naloxone. Am J Emerg Med. 2022;62:25\u201329. https:\/\/doi.org\/10.1016\/j.ajem.2022.09.041","DOI":"10.1016\/j.ajem.2022.09.041"},{"key":"22210_CR49","doi-asserted-by":"publisher","unstructured":"Pourtaher E, Payne ER, Fera N, Rowe K, Leung SJ, Stancliff S. Naloxone administration by law enforcement officers in New York State (2015\u20132020). Harm Reduct J. 2022;19(1):102. https:\/\/doi.org\/10.1186\/s12954-022-00682-w","DOI":"10.1186\/s12954-022-00682-w"},{"key":"22210_CR50","unstructured":"Drug Enforcement Administration. DEA warns of methamphetamine and fentanyl drug marker built by aftermath of COVID-19 in New York. Published January 26, 2021. Available from: https:\/\/www.dea.gov\/press-releases\/2021\/01\/26\/dea-warns-methamphetamine-and-fentanyl-drug-market-built-aftermath-covid"},{"key":"22210_CR51","unstructured":"Weiner J, Murphy SM, Behrends C. Expanding Access to Naloxone: A Review of Distribution Strategies. Issue Brief. University of Pennsylvania Leonard Davis Institute of Health Economics Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV. May 29, 2019. https:\/\/ldi.upenn.edu\/our-work\/research-updates\/expanding-access-to-naloxone-a-review-of-distribution-strategies\/"},{"key":"22210_CR52","doi-asserted-by":"publisher","unstructured":"Townsend T, Blostein F, Doan T, Madson-Olson S, Galecki P, Hutton DW. Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States. Int J Drug Policy. 2020;75:102536. https:\/\/doi.org\/10.1016\/j.drugpo.2019.07.031","DOI":"10.1016\/j.drugpo.2019.07.031"},{"key":"22210_CR53","doi-asserted-by":"publisher","unstructured":"Zang X, Bessey SE, Krieger MS, Hallowell BD, Koziol JA, Nolen S, Behrends CN, Murphy SM, Walley AY, Linas BP, Schackman BR, Marshall BDL. Comparing Projected Fatal Overdose Outcomes and Costs of Strategies to Expand Community-Based Distribution of Naloxone in Rhode Island. JAMA Netw Open 2022;5(11):e2241174. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41174","DOI":"10.1001\/jamanetworkopen.2022.41174"},{"key":"22210_CR54","doi-asserted-by":"publisher","unstructured":"Jawa R, Murray S, Tori M, Bratberg J, Walley A. Federal policymakers should urgently and greatly expand 537 naloxone access. Am J Public Health. 2022;112(4):558\u2013561. https:\/\/doi.org\/10.2105\/AJPH.2021.306699. PMID: 538 35,319,955; PMCID: PMC8961838","DOI":"10.2105\/AJPH.2021.306699"},{"key":"22210_CR55","doi-asserted-by":"publisher","unstructured":"Baker LS, Smith W, Gulley T, Tomann MM. Community perceptions of comprehensive harm reduction programs and stigma towards people who inject drugs in rural Virginia. J Community Health 2020;45(2):239\u2013244. https:\/\/doi.org\/10.1007\/s10900-019-00732-8. PMID: 31,502,098","DOI":"10.1007\/s10900-019-00732-8"},{"key":"22210_CR56","doi-asserted-by":"publisher","unstructured":"Schlosser A, Habecker P, Bevins R. Harm reduction in the Heartland: public knowledge and beliefs about naloxone in Nebraska, USA. Harm Reduct J 2022;19(1):22. https:\/\/doi.org\/10.1186\/s12954-022-00606-8. PMID: 35,246,153; PMCID: PMC8894827","DOI":"10.1186\/s12954-022-00606-8"},{"key":"22210_CR57","doi-asserted-by":"publisher","unstructured":"Doe-Simkins M, Wheeler EJ, Figgatt MC, Jones TS, Bell A, Davidson PJ. Naloxone Buyers Club: Overlooked Critical Public Health Infrastructure for Preventing Overdose Deaths. medRxiv 2021 Nov 14; https:\/\/doi.org\/10.1101\/2021.11.14.21266221. Preprint","DOI":"10.1101\/2021.11.14.21266221"},{"key":"22210_CR58","doi-asserted-by":"publisher","unstructured":"Davis CS, Carr D. Over the counter naloxone needed to save lives in the United States. Prev Med 2020;130:105932. https:\/\/doi.org\/10.1016\/j.ypmed.2019.105932. PMID: 31,770,540","DOI":"10.1016\/j.ypmed.2019.105932"},{"key":"22210_CR59","doi-asserted-by":"publisher","unstructured":"Tabatabai M, Cooper RL, Wilus DM, Edgerton RD, Ramesh A, MacMaster SA, Patel PN, Singh KP. The effect of naloxone access laws on fatal synthetic opioid overdose fatality rates. J Prim Care Community Health 2023;14:21501319221147246. https:\/\/doi.org\/10.1177\/21501319221147246. PMID: 36,625,264; PMCID: PMC9834937","DOI":"10.1177\/21501319221147246"},{"key":"22210_CR60","unstructured":"KFF 2018. The actual cost of naloxone is about a nickel. so why is the overdose reversal drug priced at over $4,000?. KFF Health News. November 19, 2018. https:\/\/kffhealthnews.org\/morning-briefing\/monday-november-19-2018\/"},{"key":"22210_CR61","unstructured":"Schreiber M. Price for drug that reverses opioid overdoses soars amid record deaths. The Guardian Oct 19, 2021. https:\/\/www.theguardian.com\/us-news\/2021\/oct\/19\/naloxone-price-soars-opioid-overdoses"},{"key":"22210_CR62","unstructured":"Kornfield M. Affordable naloxone is running out, creating a perfect storm for more overdose deaths, activists say. The Washington Post. 11 Aug 2021. https:\/\/www.washingtonpost.com\/health\/2021\/08\/11\/naloxone-demand\/ Assessed 3 Apr 2023"},{"key":"22210_CR63","unstructured":"Mudd A. Naloxone shortage could lead to thousands of overdose deaths. UNC Media Hub October 8, 2021. https:\/\/mediahub.unc.edu\/naloxone-shortage-could-lead-to-thousands-of-overdose-deaths"},{"key":"22210_CR64","unstructured":"Godvin M. The US Faces a Naloxone Shortage at the Worst Possible Time. Filter. July 29, 2021. https:\/\/filtermag.org\/us-naloxone-shortage\/"},{"key":"22210_CR65","unstructured":"Dasgupta N. \u201cCatch up on what\u2019s happening with the naloxone shortage. [Infographic].\u201d Nov 3, 2021, 11:06 AM. Tweet. https:\/\/twitter.com\/nabarund\/status\/1455914223641497610"},{"key":"22210_CR66","unstructured":"Wheeler E, Doe-Simkins M. Harm reduction programs distribute one million doses of naloxone in 2019. Medium January 2, 2020. https:\/\/medium.com\/@ejwharmreduction\/harm-reduction-programs-distribute-one-million-doses-of-naloxone-in-2019-4884d3535256"},{"key":"22210_CR67","doi-asserted-by":"publisher","unstructured":"Yang C, Favaro J, Meacham MC. NEXT Harm Reduction: An Online, Mail-Based Naloxone Distribution and Harm-Reduction Program. Am J Public Health 2021;111(4):667\u2013671. https:\/\/doi.org\/10.2105\/ajph.2020.306124. PMID: 33,600,254; PMCID: PMC7958031","DOI":"10.2105\/ajph.2020.306124"},{"key":"22210_CR68","unstructured":"Remedy Alliance distributes over 1\u00a0million doses of naloxone in the first 10 months of operation. Remedy Alliance. May 10, 2023. https:\/\/remedyallianceftp.org\/blogs\/news\/remedy-alliance-for-the-people-distributes-over-1-million-doses-of-naloxone-in-the-first-10-months-of-operation"},{"key":"22210_CR69","unstructured":"FDA (2022). Exemption and Exclusion from Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry. U.S. Department of Health and Human Services. September 22, 2022. https:\/\/www.fda.gov\/media\/161750\/download"},{"key":"22210_CR70","unstructured":"FDA (2023). FDA Approves Second Over-the-Counter Naloxone Nasal Spray Product. FDA News Release. 28 July 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-over-counter-naloxone-nasal-spray-product"},{"key":"22210_CR71","unstructured":"Harm Reduction Therapeutics (HRT), Inc. A 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making free or low-cost over-the-counter naloxone available to everyone across the United States. https:\/\/www.harmreductiontherapeutics.org"},{"key":"22210_CR72","unstructured":"Harm Reduction Therapeutics (HRT). FDA approval of RiVIVE\u2122 is a critical milestone in making emergency treatment of opioid overdose more widely available (Press Release). 28 July 2023. https:\/\/www.harmreductiontherapeutics.org\/wp-content\/uploads\/2023\/08\/HRT-RiVive-Press-Release-July-28-FINAL_DATED.pdf"},{"key":"22210_CR73","unstructured":"White House Releases State Model Law to Help Make Access to Naloxone Consistent Across the Country. November 17, 2021. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2021\/11\/17\/white-house-releases-state-model-law-to-help-make-access-to-naloxone-consistent-across-the-country\/"},{"key":"22210_CR74","unstructured":"Facher L. Biden drug czar to summon naloxone makers to White House to discuss pricing. STAT May 16, 2023. https:\/\/www.statnews.com\/2023\/05\/16\/narcan-naloxone-makers-drug-czar-pricing\/"},{"key":"22210_CR75","unstructured":"Centers for Disease Control and Prevention. Overdose Data to Action. August 9, 2023 https:\/\/www.cdc.gov\/drugoverdose\/od2a\/index.html"},{"key":"22210_CR76","unstructured":"Centers for Disease Control and Prevention. Stop Overdose. September 15, 2022 https:\/\/www.cdc.gov\/stopoverdose\/index.html"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-22210-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-22210-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T19:27:52Z","timestamp":1742930872000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-22210-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22210"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-22210-8","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This activity was reviewed by the Centers for Disease Control and Prevention (CDC) and was conducted consistent with applicable federal law and CDC policy. See e.g., 45\u00a0C.F.R. part 46; 21\u00a0C.F.R. part 56; 42 U.S.C. \u00a7\u00a0241(d), 5 U.S.C. \u00a7\u00a0552a, 44 U.S.C. \u00a7\u00a03501 et seq.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This paper does not contain any individual, personal identifying information, and accessed only previously published anonymous and aggregated data. There was no human participation or human subjects involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author disclaimer"}},{"value":"This project only used previously published anonymous and aggregated data and was determined to be \u201cExempt Human Subjects Research\u201d (under U.S. Federal statute 45 CFR 104(D) 1\u20138).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}}],"article-number":"1135"}}